EUVIMEDEUVIMED entdecken
LeitlinieOpen Access

Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes

Daniel Edmonston, Elizabeth Lydon, Hillary Mulder, Karen Chiswell, Zachary Lampron, Keith Marsolo, Ashley Goss, Isabelle Ayoub, Raj C Shah, Alexander R Chang, Daniel E Ford, W Schuyler Jones und 13 weitere

JAMA Network Open · 26.06.2024 · 7 (6) · e2418808

DOI: 10.1001/jamanetworkopen.2024.18808 ↗

Kurz gefasst

Leitlinie in der Zeitschrift JAMA Network Open, online erschienen am 26.06.2024. Verfasst von Daniel Edmonston und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Guideline Adherence. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CSRD VA, HSRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Chronic kidney disease (CKD) is an often-asymptomatic complication of type 2 diabetes (T2D) that requires annual screening to diagnose. Patient-level factors linked to inadequate screening and treatment can inform implementation strategies to facilitate guideline-recommended CKD care.

Objective

To identify risk factors for nonconcordance with guideline-recommended CKD screening and treatment in patients with T2D. Design, Setting, and Participants This retrospective cohort study was performed at 20 health care systems contributing data to the US National Patient-Centered Clinical Research Network. To evaluate concordance with CKD screening guidelines, adults with an outpatient clinician visit linked to T2D diagnosis between January 1, 2015, and December 31, 2020, and without known CKD were included. A separate analysis reviewed prescription of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors in adults with CKD (estimated glomerular filtration rate [eGFR] of 30-90 mL/min/1.73 m 2 and urinary albumin-to-creatinine ratio [UACR] of 200-5000 mg/g) and an outpatient clinician visit for T2D between October 1, 2019, and December 31, 2020. Data were analyzed from July 8, 2022, through June 22, 2023. Exposures Demographics, lifestyle factors, comorbidities, medications, and laboratory results. Main Outcomes and Measures Screening required measurement of creatinine levels and UACR within 15 months of the index visit. Treatment reflected prescription of ACEIs or ARBs and SGLT2 inhibitors within 12 months before or 6 months following the index visit.

Results

Concordance with CKD screening guidelines was assessed in 316 234 adults (median age, 59 [IQR, 50-67] years), of whom 51.5% were women; 21.7%, Black; 10.3%, Hispanic; and 67.6%, White. Only 24.9% received creatinine and UACR screening, 56.5% received 1 screening measurement, and 18.6% received neither. Hispanic ethnicity was associated with lack of screening (relative risk [RR], 1.16 [95% CI, 1.14-1.18]). In contrast, heart failure, peripheral arterial disease, and hypertension were associated with a lower risk of nonconcordance. In 4215 patients with CKD and albuminuria, 3288 (78.0%) received an ACEI or ARB; 194 (4.6%), an SGLT2 inhibitor; and 885 (21.0%), neither therapy. Peripheral arterial disease and lower eGFR were associated with lack of CKD treatment, while diuretic or statin prescription and hypertension were associated with treatment. Conclusions and Relevance In this cohort study of patients with T2D, fewer than one-quarter received recommended CKD screening. In patients with CKD and albuminuria, 21.0% did not receive an SGLT2 inhibitor or an ACEI or an ARB, despite compelling indications. Patient-level factors may inform implementation strategies to improve CKD screening and treatment in people with T2D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Renal Insufficiency, ChronicGuideline AdherenceHumansFemaleMaleMiddle AgedRetrospective StudiesAgedPractice Guidelines as TopicMass ScreeningAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsRisk FactorsSodium-Glucose Transporter 2 InhibitorsUnited StatesGlomerular Filtration Rate

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
  • Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina.
  • Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut.
  • Division of Nephrology; Department of Medicine, The Ohio State University Wexner Medical Center, Columbus.
  • Department of Family and Preventive Medicine, Rush University Medical Center, Chicago, Illinois.

Förderung

  • CSRD VA
  • HSRD VA

Zitieren

APA

Edmonston, D., Lydon, E., Mulder, H., Chiswell, K., Lampron, Z., Marsolo, K., Goss, A., Ayoub, I., Shah, R. C., Chang, A. R., Ford, D. E., Jones, W. S., Fonesca, V., Machineni, S., Fort, D., Butler, J., Hunt, K. J., Pitlosh, M., Rao, A., …, & Pagidipati, N. J. (2024). Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes. JAMA Network Open, 7(6), e2418808. https://doi.org/10.1001/jamanetworkopen.2024.18808

Vancouver

Edmonston D, Lydon E, Mulder H, Chiswell K, Lampron Z, Marsolo K, et al. Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes. JAMA Network Open. 2024;7(6):e2418808. doi:10.1001/jamanetworkopen.2024.18808

BibTeX
@article{Edmonston2024,
  author = {Edmonston, Daniel and Lydon, Elizabeth and Mulder, Hillary and Chiswell, Karen and Lampron, Zachary and Marsolo, Keith and Goss, Ashley and Ayoub, Isabelle and Shah, Raj C and Chang, Alexander R and Ford, Daniel E and Jones, W Schuyler and Fonesca, Vivian and Machineni, Sriram and Fort, Daniel and Butler, Javed and Hunt, Kelly J and Pitlosh, Max and Rao, Ajaykumar and Ahmad, Faraz S and Gordon, Howard S and Hung, Adriana M and Hwang, Wenke and Bosworth, Hayden B and Pagidipati, Neha J},
  title = {Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {6},
  pages = {e2418808},
  doi = {10.1001/jamanetworkopen.2024.18808}
}
Kostenlos starten →